- Conditions
- Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
- Interventions
- Efgartigimod
- Biological
- Lead sponsor
- M. Peter Marinkovich
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Redwood City, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–32
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Epidermolysis Bullosa Dystrophica
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Not listed
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2029
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- PTR-01
- Drug
- Lead sponsor
- Phoenix Tissue Repair, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Redwood City, California • New York, New York
- Conditions
- Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa
- Interventions
- Helicoll, Standard of Care Dressings
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- Topical beremagene geperpavec, Placebo gel
- Biological
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Squamous Cell Carcinoma
- Interventions
- BVEC
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- Gentamicin Sulfate
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- Not listed
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- Spincare matrix
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 6 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Redwood City, California